Undisclosed pan-KRAS molecular glue / Eilean Therapeutics - LARVOL DELTA

Discovery of pan-KRAS molecular glue degraders via protein-first coevolution-guided E3 ligase recruitment (AACR 2026) - "Our coevolution-guided, protein-first MGD platform enables rapid discovery of small molecules that induce pan-KRAS degradation across major oncogenic mutants. These compounds achieve degradation of KRAS protein through a proteasome-dependent mechanism, distinguishing them from covalent KRASG12C inhibitors and RAS(ON) tri-complex inhibitors. The identified pan-KRAS molecular glue degraders represent a novel therapeutic modality with potential to address the majority of KRAS-driven cancers previously considered undruggable."

Oncology • KRAS